Accelerated generation of human induced pluripotent stem cells from human oral mucosa using episomal plasmid vectors and maternal transcription factor Glis1

書誌事項

タイトル
Accelerated generation of human induced pluripotent stem cells from human oral mucosa using episomal plasmid vectors and maternal transcription factor Glis1
タイトル別名
  • エピソーマルプラスミドベクターと母性転写因子Glis1を用いたヒト口腔粘膜からのヒト人工多能性幹細胞樹立の加速化
著者
柏木, 隆宏
学位授与大学
大阪歯科大学
取得学位
博士(歯学)
学位授与番号
甲第776号
学位授与年月日
2016-03-11

説明

Objective: Induced pluripotent stem cells (iPSCs) possess high pluripotency and differentiation potential and may constitute a possible source of autologous stem cells for clinical applications. However, the lengthy reprogramming process (up to 1 month) remains one of the most significant challenges facing standard virus-mediated methodology. The transcription factor Gli-like transcription factor Glis1 is highly expressed in unfertilized eggs and one-cell-stage embryos. In this study, iPSCs were generated using a combination of primary human oral mucosa fibroblasts (HOFs) and episomal plasmid vectors expressing transcription factors including Glis1.Materials and Methods: HOFs were established from 3-mm in diameter oral mucosa tissue using the skin trephine of a 23-year-old Asian man. Human iPSCs were generated from the established HOFs using the following episomal plasmid vectors: pCXLE-hOCT3/4-shp53-F that expresses OCT3/4 and shRNA against p53; pCXLE-hSK that expresses SOX2 and KLF4; pCXLE-hUL that expresses L-MYC and LIN28; and pCXLE-hGlis1 that expresses Glis1.Results: Fifty colonies of human embryonic stem (ES)-like cells were observed as early as 20 days following initial episomal plasmid vector transduction. The resulting cell lines shared several characteristics with human ES cells, including morphology, pluripotency-associated gene and protein markers, karyotype analysis, and the ability to differentiate in vivo into all three germ layers.Conclusions: Our method, combining the use of HOFs and episomal plasmid vectors expressing OCT3/4, SOX2, KLF4, L-MYC, shRNA against p53, LIN28, and Glis1, offers a powerful tool for safely and rapidly generating bona fide human iPSCs and facilitates the application of iPSC technology to biomedical research.

2015

収集根拠 : 博士論文(自動収集)
資料形態 : テキストデータ
コレクション : 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
Objective: Induced pluripotent stem cells (iPSCs) possess high pluripotency and differentiation potential and may constitute a possible source of autologous stem cells for clinical applications. However, the lengthy reprogramming process (up to 1 month) remains one of the most significant challenges facing standard virus-mediated methodology. The transcription factor Gli-like transcription factor Glis1 is highly expressed in unfertilized eggs and one-cell-stage embryos. In this study, iPSCs were generated using a combination of primary human oral mucosa fibroblasts (HOFs) and episomal plasmid vectors expressing transcription factors including Glis1.Materials and Methods: HOFs were established from 3-mm in diameter oral mucosa tissue using the skin trephine of a 23-year-old Asian man. Human iPSCs were generated from the established HOFs using the following episomal plasmid vectors: pCXLE-hOCT3/4-shp53-F that expresses OCT3/4 and shRNA against p53; pCXLE-hSK that expresses SOX2 and KLF4; pCXLE-hUL that expresses L-MYC and LIN28; and pCXLE-hGlis1 that expresses Glis1.Results: Fifty colonies of human embryonic stem (ES)-like cells were observed as early as 20 days following initial episomal plasmid vector transduction. The resulting cell lines shared several characteristics with human ES cells, including morphology, pluripotency-associated gene and protein markers, karyotype analysis, and the ability to differentiate in vivo into all three germ layers.Conclusions: Our method, combining the use of HOFs and episomal plasmid vectors expressing OCT3/4, SOX2, KLF4, L-MYC, shRNA against p53, LIN28, and Glis1, offers a powerful tool for safely and rapidly generating bona fide human iPSCs and facilitates the application of iPSC technology to biomedical research.
2015

詳細情報 詳細情報について

問題の指摘

ページトップへ